For best results when printing this announcement, please click on link below:
RNS Number : 9402D Allergy Therapeutics PLC 08 March 2022
Allergy Therapeutics plc
("Allergy Therapeutics", the "Group" or "Company")
Allergy Therapeutics to Present at the Cowen 42nd Annual Health Care
8 March 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty
specialising in allergy vaccines, today announces that Manuel Llobet, Chief
Executive Officer, Nick Wykeman,
Chief Financial Officer, and Alan Bullimore, Head of Business Innovation of
Allergy Therapeutics, will present at the Cowen 42nd Annual Health Care
Conference taking place from 07-09 March 2022.
The presentation will review data supporting the upcoming clinical trials for
the Group's lead pipeline candidates including Grass MATA MPL, which is
expected to enter Phase III development in Q3 2022, and VLP Peanut, which is
on track to enter the clinic in the Phase I PROTECT trial later this year.
A replay of the presentation will be made available under the 'Investors'
section on Allergy Therapeutics'
- ENDS -
For further information, please contact:
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
Stern Investor Relations, Inc.
+1 212 362 1200
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
. END NRADZGGFMNNGZZZ